Prognostic Model of Postnatal Circulation in Pulmonary Atresia-critical Stenosis With Intact Ventricular Septum

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16-28
SponsorHospital Universitario 12 de Octubre

About this trial

Pulmonary atresia (PA)/critical stenosis (CS) with intact ventricular septum (PA/CS-IVS) is a rare congenital heart disease (CHD), that presents heterogeneously. Prognosis is conditioned by the possibility of achieving a primary repair with biventricular circulation (BV) or a one-and-a-half ventricle solution vs. a palliative approach bound to a univentricular (UV) circulation in which both survival and quality of life are significantly impaired. Predicting UV circulation prenatally is still a challenge.

The aim of this study is: 1/ to evaluate the natural history of the disease and develop a prognostic model for the prediction of transplantation-free survival with a biventricular or a one-and-a-half repair at 2 years postnatal age 2/ To develop a model to predict the risk of right ventricle dependent coronary circulation 3/ To evaluate prenatal and postnatal outcomes in non-intervened fetuses with a confirmed postnatal diagnosis of PA-CS/IVS including Intrauterine death, neonatal/Infant death, number of required postnatal procedures, need for oxygen support, need for cardiac transplantation

Eligibility criteria

Qualifiers

Absence of flow at the pulmonary valve (PA) or presence of thickened and domed. pulmonary valve cusps with a pinhole jet of flow.

Doppler evidence of ductal-dependent pulmonary circulation.

Intact ventricular septum.

Disqualifiers

Poor imaging windows and incomplete/poor quality scan

Termination of pregnancy

Cases initially included that undergo prenatal pulmonary valvuloplasty later on in pregnancy.

Unconfirmed PA-CS/IVS at birth.

Trial design

Treatments tested in this trial

  • No intervention

Treatment groups

150 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Hospital Universitario 12 de Octubre

Lead sponsor

Instituto de Salud Carlos III

Collaborator

Instituto de investigación Hospital 12 de Octubre

Collaborator